Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora TherapeuticsSAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) --...
Month: November 2022
Assure to Attend Investor Conferences in December 2022
DENVER, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update
Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022...
Nanomix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy
SAN LEANDRO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in...
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed...
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM”
ESTERO, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mushrooms Inc. (OTC: MSRM) (the “Company”), formerly Marijuana Strategic Ventures, Inc., is...
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents...
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of...
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November...
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics...
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq:...
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal sprayWARREN, N.J., Nov. 29,...
Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused...
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 -...
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development...
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™NEW...
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE...
Aspargo Extends Latin America Reach From Mexico to Argentina
Disrupting Erectile Dysfunction (ED) Market With Oral SprayAspargo Laboratories, Inc. to leverage Laboratorio SIDUS’ ED market position to launch Sildenafil...